<?xml version="1.0" encoding="iso-8859-1"?>
<?xml-stylesheet type="text/xsl" href="rdf.xsl"?>
<rdf:RDF  xmlns="http://purl.org/rss/1.0/"
				  xmlns:dc="http://purl.org/dc/elements/1.1/
					xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
					
<channel rdf:about="http://livepress.com">
          <title>Pharmaceuticals - livepress.com</title>
      <link>http://Pharmaceuticals.livepress.com</link>
      <description>Updated every 15 minutes of every day - FOR PERSONAL USE ONLY</description>
  <dc:publisher>livepress.com</dc:publisher>
  <dc:creator>livepress.com</dc:creator>
  <dc:rights>Copyright &#169; 2006 livepress.com</dc:rights>
  <sy:updatePeriod>hourly</sy:updatePeriod>
  <sy:updateFrequency>2</sy:updateFrequency>
  <items>
    <rdf:Seq>
      <rdf:li rdf:resource="http://livepress.com" />
    </rdf:Seq>
  </items>
</channel>
<item rdf:about="http://livepress.com/go/?136205">
  		<title><![CDATA[Hospira net falls as expenses jump 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?136205</link>
  		  		<dc:description><![CDATA[Reuters - Hospira Inc. , which makes 
specialty  pharmaceuticals  and medication-delivery systems, on 
Wednesday said quarterly earnings fell 25 percent as sales were 
nearly flat and expenses surged.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?135544">
  		<title><![CDATA[Barr to refile contraceptive bid within 2 weeks 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?135544</link>
  		  		<dc:description><![CDATA[    Reuters - Barr  Pharmaceuticals  Inc.  
aims to resubmit its application to sell its Plan B 
morning-after contraceptive pill within two weeks, the company 
said on Tuesday, following a meeting with U.S. Food and Drug 
Administration officials.  ]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?130359">
  		<title><![CDATA[FDA, Barr to discuss looser Plan B sales 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?130359</link>
  		  		<dc:description><![CDATA[Reuters - The U.S. Food and Drug 
Administration and Barr  Pharmaceuticals  Inc.  will meet 
to discuss the possible approval of nonprescription sales of 
the Plan B "morning-after" contraceptive to women 18 and older, 
the agency said on Monday.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?130351">
  		<title><![CDATA[FDA to talk with Barr on Plan B proposal 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?130351</link>
  		  		<dc:description><![CDATA[Reuters - The U.S. Food and Drug 
Administration will meet with officials from Barr 
 Pharmaceuticals  Inc.  to discuss the possible approval 
of nonprescription sales of the Plan B "morning-after" 
contraceptive to women 18 and older, the agency said on Monday.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?124887">
  		<title><![CDATA[FDA clears AstraZeneca asthma drug 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?124887</link>
  		  		<dc:description><![CDATA[    Reuters - AstraZeneca Plc  has won U.S. 
approval for its asthma drug Symbicort, significantly earlier 
than most industry analysts had expected, a person familiar 
with the matter said on Saturday.  ]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?97032">
  		<title><![CDATA[Barr enters bidding race to buy Pliva: report 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?97032</link>
  		  		<dc:description><![CDATA[Reuters - U.S. drug maker Barr  Pharmaceuticals  
 has entered the bidding for Croatian pharmaceutical 
group Pliva (PLVxq.L), the Financial Times newspaper said on 
Monday.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?85269">
  		<title><![CDATA[Barr says Lilly sues to stop generic weekly Prozac 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?85269</link>
  		  		<dc:description><![CDATA[Reuters - Barr  Pharmaceuticals  Inc.  on 
Thursday said  Eli Lilly  & Co.  has sued the company, 
claiming Barr's generic weekly form of anti-depressant Prozac 
infringes the patent on Lilly's branded medicine.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?84676">
  		<title><![CDATA[Animal Rights Activists Target Glaxo Investors]]></title>
	  	<link>http://livepress.com/go/?84676</link>
  		  		<dc:description><![CDATA[ Europe's biggest  pharmaceuticals  manufacturer, GlaxoSmithKline, says shareholders were told they would have their details posted on the internet if they did not sell their shares within 14 days in a threatening letter by animal rights...]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?82436">
  		<title><![CDATA[Ariad's Shares Climb 40 Percent After It Wins Patent Case]]></title>
	  	<link>http://livepress.com/go/?82436</link>
  		  		<dc:description><![CDATA[ Ariad  Pharmaceuticals  Inc. shares climbed up to 40 percent on Thursday after the company announced it won a patent infringement case against  Eli Lilly  and Co.
 Reuters reports a federal court in Massachusetts decided that Lilly's osteoporosis...]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?72353">
  		<title><![CDATA[Texas plaintiffs seek over $1 bln in Vioxx case 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?72353</link>
  		  		<dc:description><![CDATA[    Reuters - Attorneys suing  Merck  &amp; 
Co. Inc.  for the death of a 71-year-old man who took 
Vioxx asked a Texas jury on Thursday to award more than &#36;1 
billion in damages, but  Merck  lawyers said the  pharmaceuticals  
company should not have to pay anything.  ]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?65643">
  		<title><![CDATA[DrugMax announces preliminary Q1 results 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?65643</link>
  		  		<dc:description><![CDATA[Reuters -  Pharmaceuticals  distributor DrugMax Inc. 
 reported preliminary results for the first quarter on 
Monday.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?60964">
  		<title><![CDATA[FDA halts Cortex's sleep drug trial, shares plunge 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?60964</link>
  		  		<dc:description><![CDATA[Reuters - Cortex  Pharmaceuticals  Inc.  shares lost 
almost half of their value in morning trade Monday after the 
U.S. Food and Drug Administration placed the clinical trial of 
the company's sleep disorder drug on hold.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?56849">
  		<title><![CDATA[SGX forges leukemia cancer deal with Novartis 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?56849</link>
  		  		<dc:description><![CDATA[Reuters - SGX  Pharmaceuticals  Inc.  late 
on Monday said Swiss drugmaker Novartis AG  had 
licensed its experimental drugs to treat leukemia and could 
eventually pay it more than $515 million under the deal.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?55021">
  		<title><![CDATA[King may need new trial for Altace for kids 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?55021</link>
  		  		<dc:description><![CDATA[Reuters - King  Pharmaceuticals , Inc.  on 
Friday said U.S. regulators have determined that clinical data 
on use by children of its Altace hypertension drug was 
insufficient and a new trial may be needed.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?41185">
  		<title><![CDATA[Shire sues Teva over generic Adderall XR plans 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?41185</link>
  		  		<dc:description><![CDATA[Reuters - British drugmaker Shire Plc  said 
on Friday it was suing Teva  Pharmaceuticals   over the 
Israeli drugmaker's plans to make a cheap, copycat version of 
hyperactivity drug Adderall XR.]]></dc:description>
  				</item>
<item rdf:about="http://livepress.com/go/?38894">
  		<title><![CDATA[King Pharma posts quarterly net loss 
    (Reuters)
]]></title>
	  	<link>http://livepress.com/go/?38894</link>
  		  		<dc:description><![CDATA[Reuters - Drugmaker King  Pharmaceuticals  Inc. 
 on Tuesday posted a quarterly loss after taking a large 
charge tied to a research deal.]]></dc:description>
  				</item>
</rdf:RDF>